ABSTRACT PRESENTERS of accepted abstracts are required to register for the meeting at the corresponding member or nonmember rate. All abstracts submitted by the August 3 deadline will be considered for poster presentation.

If an abstract is not selected for presentation, the presenter may request a full refund of the registration fee by contacting the AACR Meetings Department at [email protected]. This supports an approach combining targeted agents with immune checkpoint inhibitors even in BRAF WT melanoma. If an abstract is not accepted for presentation at the conference, the presenter may request a full refund of the registration fee. before submitting. Preclinical and clinical studies show that MEK inhibition can actually enhance the T-cell response at the site of the tumor by selectively eliminating naïve T cells; CDK4/6 inhibition can influence PD-L1 expression and induce retroviral sequences, which then induce an inflammatory (hot) tumor microenvironment. Thank you for sharing this Cancer Research article. Email: [email protected], Cancer Researchers / Other Health Care Professionals, AACR Virtual Special Conference: Tumor Immunology and Immunotherapy, Innovation and Biomarkers in Cancer Drug Development, EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Accelerating Anticancer Agent Development, EORTC-ESMO-AACR Methods in Clinical Cancer Research Workshop, AACR/ASCO Methods in Clinical Cancer Research, Translational Cancer Research for Basic Scientists, AACR Project GENIE: Powering Precision Medicine, Scientific Achievement Awards and Lectureships, Science Policy and Government Affairs Committee, Education and Inspiration for Patient Advocates, Patient Advocate Programs at the AACR Annual Meeting, The Evolving Tumor Microenvironment in Cancer Progression, AACR Virtual Meetings: Access and Browser Requirements, Meetings, Conferences, and Workshops Under Development, Scholar-in-Training Awards: Annual Meeting, AACR Minority Scholar in Cancer Research Awards, AACR Minority and Minority-serving Institution Faculty Scholar in Cancer Research Awards, AACR Scholar-in-Training Awards: Other Conferences and Meetings, The Immune Tumor Microenvironment: Blood-Derived versus Tissue-Resident, Longitudinal Monitoring of the Elusive Tumor Cells, The Organ-Specific Metastatic Niches: They Are Not All Created Equal, Systemic Drivers of Progression: Aging to Obesity, The Therapy-Treated Tumor Microenvironment: Impact on the Preneoplastic versus Premetastatic Niche, The Tumor Microenvironment Drives Tumor Cell Fate, Tumor progression: Mechano-Signaling and Control.

Abstracts: AACR Special Conference on Melanoma: From Biology to Target; January 15-18, 2019; Houston, TX Molecular targeting of melanoma beyond the BRAFV600 mutation has been a frustrating and largely unsuccessful pursuit.

All individuals listed as ABSTRACT PRESENTERS will be notified of acceptance or rejection by email in late August.

ET.

If an abstract is not selected for presentation, the presenter may request a full refund of the registration fee by contacting the AACR Meetings Department at [email protected]. Only those abstracts that have been reviewed and selected by the Conference Program Committee may be presented. On the other hand, there is further evidence that the microenvironment may be critical for targeted therapy to be effective. American Journal of Cancer ISSN: 0099-7374, Abstracts: AACR Special Conference on Melanoma: From Biology to Target; January 15-18, 2019; Houston, TX, Sign In to Email Alerts with your Email Address.

615 Chestnut St., 17th Floor Notices and instructions will be sent to the email address provided at the time of abstract submission. Cancer Research Print ISSN: 0008-5472 Accepted abstracts will also be published as an online-only Proceedings supplement to an AACR journal after the completion of the conference.

These approaches have been frequently plagued by significant toxicity.

If you are an AACR member, please use your AACR username and password. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. Are there nonimmune targets in the BRAFV600 WT melanoma patient? Copyright © 2020 by the American Association for Cancer Research.

If you have forgotten either, you can look it up on the website by entering your Member ID. Links to abstract titles and poster presenters assigned to each session are listed below. This effort has concentrated on the inhibition of the activated MAPK pathway with MEK inhibitors and targeted NRAS tumors, which make at least 1/3 of the non-BRAF V600 mutant melanoma.

Email: [email protected], Cancer Researchers / Other Health Care Professionals, AACR Virtual Special Conference: Tumor Immunology and Immunotherapy, Innovation and Biomarkers in Cancer Drug Development, EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Accelerating Anticancer Agent Development, EORTC-ESMO-AACR Methods in Clinical Cancer Research Workshop, AACR/ASCO Methods in Clinical Cancer Research, Translational Cancer Research for Basic Scientists, AACR Project GENIE: Powering Precision Medicine, Scientific Achievement Awards and Lectureships, Science Policy and Government Affairs Committee, Education and Inspiration for Patient Advocates, Patient Advocate Programs at the AACR Annual Meeting, The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, AACR Virtual Meetings: Access and Browser Requirements, Meetings, Conferences, and Workshops Under Development, Scholar-in-Training Awards: Annual Meeting, AACR Minority Scholar in Cancer Research Awards, AACR Minority and Minority-serving Institution Faculty Scholar in Cancer Research Awards, AACR Scholar-in-Training Awards: Other Conferences and Meetings. Many of these approaches continue to be pursued in the clinic in the hope that different schedules will be more effective and less toxic. To further refine your search, toggle appropriate sections on or off.

If you have any questions or experience any problems, please contact AACR Abstract Support at [email protected]. Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results.

AACR Meeting Abstracts; Upcoming Meetings Upcoming Meetings.

An obvious target has been inhibition of downstream pERK which has shown some limited clinical activity. Either inhibiting autophagy or enhancing Bim-directed apoptosis is also under investigation. Accepted abstracts will also be published as an online-only Proceedings supplement to an AACR journal after the completion of the conference. Abstract Submission Deadline Thursday, November 12, 2020, 12 p.m. If an abstract is not selected for presentation, the presenter may request a full refund of the registration fee by contacting the AACR Meetings Department at [email protected]. Accepted abstracts must remain confidential until that time. Cancer Research Online ISSN: 1538-7445

Telephone: 215-440-9300

Citation Format: Jeffrey A. Sosman.

Attacking other pathways looks promising, including targeting mitotic kinases, such as PLK1 and Aurora kinase A. The dominant driver in many of these cases is the gain of function NRAS mutations, while a smaller subset are in part driven by NF1 loss of function genetic alterations, … Additionally, oral presentations of highly rated abstracts will be integrated within thematic sessions. For non-AACR members, you will need to create a free myAACR account to submit your abstract. If you submitted an abstract to the terminated live event, it will automatically be reviewed and considered for e-presentation at the Conference. Abstracts are no longer being accepted for this conference. Notices and instructions will be sent to the email address provided at the time of abstract submission.

For additional information, please visit the registration webpage.

Abstracts selected to be presented at this virtual conference will be available as a .pdf file to conference registrants at the start of the virtual conference. Abstract Submission Deadline Thursday, November 12, 2020, 12 p.m. Please Note: All session times for the AACR Special Conference: The Evolving Tumor Microenvironment in Cancer Progression; Mechanisms and Emerging Therapeutic Opportunities are U.S. Eastern Daylight Time (EDT). Please Note: All session times for the AACR Special Conference: The Evolving Tumor Microenvironment in Cancer Progression; Mechanisms and Emerging Therapeutic Opportunities are U.S. Eastern Daylight Time (EDT). Withdrawal requests must be emailed to [email protected] by Monday, December 28, 2020, 615 Chestnut St., 17th Floor Once an abstract has been submitted, it may be withdrawn only by written request from the ABSTRACT PRESENTER.

All accepted abstracts will be presented as posters during Poster Session A on Tuesday, January 14, from 4:15-6:45 p.m. or Poster Session B on Thursday, January 15, from 12:30-3 p.m.

Please be sure to carefully check your abstract for content errors, spelling, names, etc. ET Individuals interested in submitting an abstract for presentation during the conference must do so through the … You can create, modify, and submit abstracts until the November 19, 2020, abstract … Details on the length and format of the presentations will be provided to individuals noted as ABSTRACT PRESENTERS of accepted abstracts.

To further refine your search, toggle appropriate sections on or off.

In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA24. Individuals interested in submitting an abstract for presentation during the conference must do so through the New AACR Online Submission System below.

Molecular targeting of melanoma beyond the BRAFV600 mutation has been a frustrating and largely unsuccessful pursuit. The request may be emailed to [email protected] and must be received at least 30 days prior to the start of the conference. Philadelphia, PA 19106-4404  USA All individuals listed as ABSTRACT PRESENTERS will be notified of acceptance or rejection by email approximately six weeks after the abstract submission deadline. Enter multiple addresses on separate lines or separate them with commas.